Evidence map›Paper›PMID 41350757›Full record

ArticleStatistics in medicine2025

Covariate-Adjusted Group Sequential Comparisons of Survival Probabilities.

Peter Zhang, Brent Logan, Michael J Martens

Registry-linked trialAbstract read
In one paragraph

Article in Statistics in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01597778 (A Multi-Center, Phase III, Randomized Trial of RIC and Transplantation of), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01597778 phase3completednot on this map

A Multi-Center, Phase III, Randomized Trial of RIC and Transplantation of (dUCB) Versus HLA-Haplo Related Bone Marrow for Patients With Hematologic Malignancies.(BMT CTN #1101)

TypeinterventionalSponsorMedical College of WisconsinRan2012 to 2020Enrolled368ConditionsAcute Lymphocytic Leukemia, Acute Myelogenous Leukemia, Burkitt's Lymphoma, Follicular LymphomaArmsHaploidentical Bone Marrow Transplant, Double Umbilical Cord Blood Transplant
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Peter ZhangDivision of Biostatistics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.ORCID https://orcid.org/0000-0002-2097-8212
Brent LoganDivision of Biostatistics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Michael J MartensDivision of Biostatistics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.

Funding

Data Resource for Analyzing Blood &Marrow TransplantsU24CA076518 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI Amy M Moskop, Bronwen Shaw · 1998 to 2026
$105.2M
Blood and Marrow Transplant Clinical Trials Network DCC- The Medical College of Wisconsin, Inc.U24HL138660 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI Steven M. DeVine, Mehdi Hussain Hamadani · 2017 to 2026
$71.4M
Easy-to-read Informed Consent for HCT Clinical TrialsU10HL069294 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI HOROWITZ, MARY MARESCA · 2011 to 2016
$43.8M
Health Resources and Services Administration, Department of Health and Human Services HHSH234200637015CHealth Resources and Services Administration, Department of Health and Human Services HHSH250201200016CNational Institute of Allergy and Infectious Diseases 5U24CA076518NCI NIH HHS U24 CA076518NHLBI NIH HHS U10 HL069294NHLBI NIH HHS U10HL069294NHLBI NIH HHS U24 HL138660NHLBI NIH HHS U24HL138660Office of Naval Research N00014-16-1-2020Office of Naval Research N00014-17-1-2388
6 · The paper itself

Abstract

In confirmatory clinical trials, survival outcomes are frequently studied and interim analyses for efficacy and/or futility are often desirable. Methods including the log rank test and Cox regression model are commonly used for treatment comparisons, but are most efficient in a proportional hazards (PH) setting and are subject to a loss of power when PH are violated. Such violations may be expected a priori, particularly when the mechanisms of treatments differ such as immunotherapy versus chemotherapy for treating cancer. We propose group sequential tests for comparing survival probabilities with covariate adjustment that allow for interim analyses in the presence of non-PH and offer easily interpreted, clinically meaningful summary measures of the treatment effect. The joint distribution of repeatedly computed test statistics possesses an independent increments structure asymptotically, facilitating marginal comparisons of survival probabilities in sequential studies by simplifying critical value specification to maintain Type I error control and sample size/power determination. Simulations demonstrate that the Type I error rate and power of the proposed tests meet targeted levels and are robust to the PH assumption and covariate influence. The proposed tests are illustrated using the Blood and Marrow Transplant Clinical Trials Network 1101 trial data ( https://www.clinicaltrials.gov #NCT01597778).

Indexed as

ProbabilitySurvival AnalysisBone Marrow TransplantationClinical Trials, Phase III as TopicComputer SimulationData Interpretation, StatisticalHumansModels, StatisticalMulticenter Studies as TopicProportional Hazards ModelsRandomized Controlled Trials as Topicadjusted survival probabilityblood and marrow transplantationcovariate adjustmentgroup sequential designnonproportional hazards

Identifiers

PMID41350757
PMCPMC12822512

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.